These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29718530)

  • 41. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
    Langenickel TH; Jordaan P; Petruck J; Kode K; Pal P; Vaidya S; Chandra P; Rajman I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):917-24. PubMed ID: 27083930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats.
    Imran M; Hassan MQ; Akhtar MS; Rahman O; Akhtar M; Najmi AK
    Clin Exp Hypertens; 2019; 41(1):62-69. PubMed ID: 29595329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
    Sun J; Xu W; Hua H; Xiao Y; Chen X; Gao Z; Li S; Jing X; Du F; Sun G
    Biomed Pharmacother; 2020 Sep; 129():110410. PubMed ID: 32570118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sacubitril/valsartan alleviates sepsis-induced myocardial injury in rats via dual angiotensin receptor-neprilysin inhibition and modulation of inflammasome/caspase 1/IL1β pathway.
    Refaie MMM; El-Hussieny M; Bayoumi AMA; Abdelraheem WM; Abdel-Hakeem EA; Shehata S
    Eur J Pharmacol; 2024 Sep; 979():176834. PubMed ID: 39038638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome.
    Li Y; Kang L; Rong K; Zhang Y; Suo Y; Yuan M; Bao Q; Shao S; Tse G; Li R; Liu T; Li G
    Life Sci; 2021 Sep; 280():119692. PubMed ID: 34102189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice.
    Zhang H; Liu G; Zhou W; Zhang W; Wang K; Zhang J
    Sci Rep; 2019 Apr; 9(1):6509. PubMed ID: 31019233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Xanthohumol attenuates isoprenaline-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway.
    Sun TL; Li WQ; Tong XL; Liu XY; Zhou WH
    Eur J Pharmacol; 2021 Jan; 891():173690. PubMed ID: 33127362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
    Chrysant SG
    J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
    Li X; Braza J; Mende U; Choudhary G; Zhang P
    Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
.
    Ayalasomayajula S; Langenickel TH; Chandra P; Wolfson ED; Albrecht D; Zhou W; Pal P; Rajman I; Sunkara G
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1012-1018. PubMed ID: 27719743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
    Chaumais MC; Djessas MRA; Thuillet R; Cumont A; Tu L; Hebert G; Gaignard P; Huertas A; Savale L; Humbert M; Guignabert C
    Cardiovasc Res; 2021 Apr; 117(5):1391-1401. PubMed ID: 32653925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
    Ayalasomayajula SP; Langenickel TH; Jordaan P; Zhou W; Chandra P; Albrecht D; Pal P; Rajman I; Sunkara G
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1065-73. PubMed ID: 27230850
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
    Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.
    Schoenfeld HA; West T; Verghese PB; Holubasch M; Shenoy N; Kagan D; Buono C; Zhou W; DeCristofaro M; Douville J; Goodrich GG; Mansfield K; Saravanan C; Cumin F; Webb RL; Bateman RJ
    Toxicol Appl Pharmacol; 2017 May; 323():53-65. PubMed ID: 28315356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates epithelial-mesenchymal transition of peritoneal mesothelial cells and M2 macrophage polarization.
    Hu Y; Zhou C; Zhong Q; Li X; Li J; Shi Y; Ma X; Jiang D; Wang Y; Zhuang S; Liu N
    Ren Fail; 2024 Dec; 46(2):2392849. PubMed ID: 39165231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
    Akahori M; Ayalasomayajula S; Langenickel T; Pal P; Zhou W; Sunkara G
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):407-416. PubMed ID: 27324506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
    Lillyblad MP
    Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.